The global healthcare landscape faces an unprecedented moral and logistical challenge: approximately 400 million people worldwide are collectively living with a rare disease. Despite significant strides in scientific research over the past decade—including the rapid evolution of genomic sequencing, novel therapeutic modalities, and advanced in silico modeling—a profound disconnect remains between discovery and delivery. For millions of patients, therapeutic advancements mean nothing if access, reimbursement, and systemic economic hurdles prevent life-saving drugs from reaching the clinic.
These pressing concerns formed the core agenda of the inaugural 2026 DIA-MHRA Global Summit, held in London during London Life Sciences Week. The landmark event brought together global regulators, industry leaders, biotechnology pioneers, and patient advocates to confront the barriers plaguing the rare disease ecosystem. Central to the discussions was an urgent call for sweeping regulatory reform, enhanced clinical trial designs, and the integration of artificial intelligence (AI) to streamline drug development and revolutionize patient access.
Personal Narratives and the Reality of the Access Gap
The human toll of the rare disease crisis was brought into sharp focus during a deeply personal fireside chat featuring former UK Prime Minister David Cameron and Julia Vitarello, founder and CEO of Mila’s Miracle Foundation. Both leaders spoke from the perspective of parents who lost children to rare, devastating conditions—Cameron’s son Ivan suffered from Ohtahara syndrome, while Vitarello’s daughter Mila battled Batten disease.
While Ivan passed away before any targeted treatment options could be developed for his specific condition, Mila became a global medical milestone. Following what Vitarello described as a "Herculean effort" and a protracted battle with Boston Children’s Hospital, Mila received a custom-engineered, mutation-specific therapy one year after her diagnosis, making her the recipient of the world’s first individualized medicine.
"Mila set a record in the world that has snowballed into where we are today," Vitarello told attendees. However, she was quick to caveat that Mila’s case remains an extraordinary exception. The vast majority of children and adults diagnosed with rare conditions are still unable to access life-saving treatments, trapped behind bureaucratic delays, financial constraints, and rigid regulatory frameworks that fail to account for ultra-low patient populations.
The Convergence of AI and Genomic Medicine in Drug Discovery
As policymakers grapple with access challenges, the technological landscape is undergoing a seismic shift. The ongoing artificial intelligence revolution is fundamentally transforming drug discovery, moving far beyond traditional laboratory frameworks into real-time genetic editing and predictive modeling.
Professor Fyodor Urnov, director of therapeutic R&D at the Innovative Genomics Institute (IGI) and professor of molecular and cell biology at UC Berkeley, highlighted the breathtaking velocity of modern genetic engineering. Having played a pivotal role in creating a bespoke treatment for "Baby KJ," Urnov noted that it currently takes approximately one month to design a clinic-grade gene editor for a specific mutation targeting immune, metabolic, blood, liver, and skin conditions.

Looking toward the near future, Urnov revealed ongoing collaborations with technology giants Anthropic and OpenAI aimed at compressing that design cycle to a mere 12 hours. Such a leap would represent an absolute paradigm shift for patients suffering from monogenic rare diseases, allowing treatments to be custom-tailored on demand.
Former Prime Minister David Cameron echoed these sentiments, emphasizing that the synthesis of genomics and AI will permanently alter how healthcare systems manage rare diseases. Even in cases where a direct commercial cure is not immediately available, advanced diagnostic frameworks will provide families with definitive answers regarding the origin and mechanisms of a disease, improving long-term care management.
Innovations in Clinical Trials: In Silico Modeling and Digital Twins
Clinical trial recruitment and retention have historically served as major bottlenecks in rare disease development. Because patient populations are inherently small and geographically dispersed, traditional randomized controlled trials (RCTs) are often practically impossible, statistically underpowered, or ethically questionable.
To bypass these hurdles, experts at the summit pointed to the growing prominence of in silico modeling and digital twins. Professor Hisham Aljadhey, CEO of the Saudi Food and Drug Administration (SFDA), underscored
the necessity of computational scaling for rare disease therapeutics. Meanwhile, Professor Michael von Forstner, chief scientific officer of MedGenie, detailed how digital twins are set to disrupt conventional trial protocols.
Digital twins synthesize individual patient data, advanced biological modeling, and personalized parameters to construct virtual simulations of human physiology. By predicting how a specific pediatric patient is likely to respond to a candidate therapy, researchers can circumvent the ethical dilemmas of placebo-controlled randomization while generating robust predictive data for regulatory submission.
Furthermore, Kevin Lee, CEO of UK-based biotech firm Bicycle Therapeutics, noted that integrating these advanced technologies across the entire value chain—from initial discovery and preclinical development to clinical trials and manufacturing—will ultimately drive down the exorbitant costs associated with orphan drug development.
Reinventing Research Design, P-Values, and Data Collection
Addressing the structural inefficiencies of rare disease research requires a complete reimagining of traditional trial designs and data collection methodologies. Industry leaders at the summit argued that legacy standards established for common, high-prevalence diseases are wholly unsuited for the orphan drug space.

Chris Hollowood, CEO and chief investment officer of Syncona Investment Management, called for greater regulatory flexibility regarding statistical significance thresholds, specifically advocating for staggered p-values in rare disease trials.
"If you’ve taken a gene insertion that sits on a platform that’s already been to clinic in a monogenic recessive disorder, that p-value should not be 0.05," Hollowood explained. He argued that if regulators implemented staggered benchmarks—such as 0.05 for a first-in-class platform, 0.1 for a second, and 0.15 for subsequent iterations—it would substantially de-risk commercial investment without compromising patient safety.
In parallel with flexible trial designs, experts stressed the critical importance of expansive data collection frameworks. David Cameron strongly advocated for population-wide newborn genomic screening, arguing that limiting screenings exclusively to conditions with pre-existing, approved therapies is a systemic mistake. Broad-spectrum genomic screening builds comprehensive epidemiological databases that not only assist clinical researchers in understanding disease etiology but also create readily accessible patient pools for future clinical trial recruitment.
Regulatory Evolution: The UK’s Rare Disease Framework and Aligned Pathways
While scientific and technological innovations are accelerating at an unprecedented pace, global regulatory structures have historically lagged behind. Both regulators and industry stakeholders now widely acknowledge that traditional approval pathways are unsustainable for rare and ultra-rare conditions.
In response to these systemic pressures, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) introduced the Rare Disease Framework. This initiative establishes a flexible, risk-proportionate regulatory environment designed to fast-track therapeutic development and expand patient access. During summit panel discussions, Professor Urnov emphasized that risk proportionality must remain the cornerstone of modern rare disease regulation, given that the extreme severity and high patient burden of these conditions inherently justify greater regulatory agility.
Moreover, the MHRA is actively collaborating with the National Institute for Health and Care Excellence (NICE) via an aligned regulatory and health technology assessment pathway. By synchronizing regulatory approvals with National Health Service (NHS) reimbursement and commissioning decisions, the initiative aims to slash up to six months off the timeline required for breakthrough medicines to reach British patients.
Broader Implications and the Path Forward
The inaugural 2026 DIA-MHRA Global Summit concluded with a clear consensus: solving the global rare disease crisis requires a synchronized, multi-stakeholder overhaul of the entire healthcare ecosystem.
As artificial intelligence compresses genetic engineering timelines, digital twins redefine clinical trial ethics, and regulators adopt more risk-proportionate frameworks, the architecture is slowly falling into place to transform rare disease management. However, experts warn that sustained political will, cross-border data sharing, and innovative reimbursement models will be essential to ensure that the 400 million people living with rare diseases are no longer left behind by the march of medical progress.














